FDA Brief

Warning letters Drugs

FDA warning letter to

Proquimes S A Productos Quimicos Especializados S.A.

High riskIssued Apr 5, 2021Posted Apr 13, 2021Center for Drug Evaluation and Research

FDA warned Proquimes S.A. that its active pharmaceutical ingredient manufacturing violated current good manufacturing practice (CGMP) because process, equipment, and cleaning validation were missing.

What happened

FDA reviewed records Proquimes submitted after FDA's April 16, 2020 request under section 704(a)(4) and later communication. The company said it had not performed process validation, equipment qualification, or cleaning validation for a USP API (an API meeting the U.S. Pharmacopeia standard) it distributed to the United States, and it did not test each incoming component lot for identity. FDA placed all drugs made by the firm on Import Alert 66-40, which can stop U.S. imports, on December 3, 2020.

What FDA found

  1. The company did not validate its manufacturing process, so it could not show the process consistently makes API meeting quality attributes.

    FD&C Act section 501(a)(2)(B)
  2. The company did not qualify critical manufacturing equipment and called the equipment "unqualified."

    FD&C Act section 501(a)(2)(B)
  3. The company did not validate cleaning procedures for shared API equipment, risking cross-contamination.

    FD&C Act section 501(a)(2)(B)
  4. The company did not test each incoming production material lot for identity, citing lack of resources.

    FD&C Act section 501(a)(2)(B)

What FDA wants

FDA tells Proquimes to respond in writing within 15 working days with corrective actions for all cited deviations and a schedule if it cannot meet that deadline. FDA also recommends a qualified CGMP consultant and says the import alert can remain until the firm resolves the issues and FDA confirms compliance.

Who should pay attention

  • drugmakers buying API from Proquimes
  • brands with products using API from this site
  • supplier quality teams tracking Import Alert 66-40

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  3. Sanrace Biotechnology Co., Ltd.

    FDA warns Sanrace Biotechnology over CGMP failures in OTC drugs, including missing identity tests and no process validation.

    High risk
  4. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk